Controlled ovarian hyperstimulation: are we monitoring the appropriate sex-steroid hormones?

Fertility and Sterility

Volumn 89, Issue 5, 2008, Pages 1269-1272

  Orvieto, Raoul ^a,b   Hod, Eduard ^a   Volodarsky, Michael ^a   Homburg, Roy ^a   Rabinson, Jacob ^a   Meltcer, Simion ^a  

^a BARZILAI MEDICAL CENTER   (Israel)

^b BEN GURION UNIVERSITY OF THE NEGEV   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN; ESTRADIOL; GONADOTROPIN; HYDROXYPROGESTERONE; PROGESTERONE; SEX HORMONE;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED OVARIAN HYPERSTIMULATION; CONTROLLED STUDY; ESTRADIOL BLOOD LEVEL; FEMALE; FEMALE INFERTILITY; FERTILIZATION IN VITRO; HUMAN; INFERTILITY THERAPY; MENSTRUAL CYCLE; OVARY HYPERSTIMULATION; PATIENT MONITORING; PRIORITY JOURNAL; PROGESTERONE BLOOD LEVEL;

17-ALPHA-HYDROXYPROGESTERONE; ADULT; BIOLOGICAL MARKERS; C-REACTIVE PROTEIN; ESTRADIOL; FEMALE; FERTILIZATION IN VITRO; HUMANS; OVARIAN HYPERSTIMULATION SYNDROME; OVULATION INDUCTION; PROGESTERONE; PROSPECTIVE STUDIES;

EID: 43449101187     PISSN: 00150282     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.fertnstert.2007.05.024     Document Type: Article

References (14)

1. Fleischer A.C., Daniell J.F., Rodier J., Lindsay A.M., and James Jr. A.E. Sonographic monitoring of ovarian follicular development. J Clin Ultrasound 9 (1981) 275-280
2. Tarlatzis B.C., Laufer N., and DeCherney A.H. The use of ovarian ultrasonography in monitoring ovulation induction. J In Vitro Fert Embryo Transf 1 (1984) 226-232
3. Orvieto R., Yulzari-Roll V., La-Marca A., Ashkenazi J., and Fisch B. Serum androgen levels in patients undergoing controlled ovarian hyperstimulation for in vitro fertilization cycle. Gynecol Endocrinol 21 (2005) 218-222
4. Orvieto R., Zohav E., Scharf S., Rabinson J., Meltcer S., Anteby E., et al. The influence of E2/follicle and E2/oocyte ratios on the outcome of controlled ovarian stimulation for in-vitro fertilization. Gynecol Endocrinol 23 (2007) 72-75
5. Orvieto R. Controlled ovarian hyperstimulation-an inflammatory state. J Soc Gynecol Invest 11 (2004) 424-426
6. Orvieto R., Chen R., Ashkenazi J., Ben-Haroush A., Bar J., and Fisch B. C-reactive protein levels in patients undergoing controlled ovarian hyperstimulation for in vitro fertilization cycle. Hum Reprod 19 (2004) 357-359
7. Sacks G.P., Seyani L., Lavery S., and Trew G. Maternal C-reactive protein levels are raised at 4 weeks' gestation. Hum Reprod 19 (2004) 1025-1030
8. Ben Shlomo I., Geselevich J., and Shalev E. Can we abandon routine evaluation of serum estradiol levels during controlled ovarian hyperstimulation for assisted reproduction?. Fertil Steril 76 (2001) 300-303
9. Orvieto R. Prediction of ovarian hyperstimulation syndrome. Challenging the estradiol mythos. Hum Reprod 18 (2003) 665-667
10. Tadmor O.P., Kleinman Y., Barr I., Gal M., Brooks B.A., and Diamant Y.Z. Side effects of ovarian hyperstimulation: hormonal and lipid profile changes. Int J Fertil Menopausal Stud 39 (1994) 105-110
11. Mango D., Scirpa P., Spina M.A., Battaglia F., Tartaglia E., Manna P., et al. Ultrasonic and endocrinologic relationships in spontaneous and induced follicular phase. J Endocrinol Invest 11 (1988) 7-13
12. Speroff L., and Fritz M.A. Clinical gynecological endocrinology and infertility. 7th ed. (2005), Lippincott Williams & Wilkins, Philadelphia 1226
13. Orvieto R, Zagatski I, Yulzari-Roll V, La-Marca A, Fisch B. Substituting hCG by GnRH-agonist to trigger final follicular maturation, during controlled ovarian hyperstimulation, results in less systemic inflammation. Gynecol Endocrinol 206;22:437-40.
14. Orvieto R., Fisch N., Yulzari-Roll V., and La-Marca A. Ovarian androgen but not estrogen correlates with the degree of systemic inflammation observed during controlled ovarian hyperstimulation. Gynecol Endocrinol 21 (2005) 170-173